Literature DB >> 19826448

Mast cell stabilizing properties of antihistamines.

Francesca Levi-Schaffer1, Ron Eliashar.   

Abstract

Histamine is a key mediator of allergic inflammation, primarily through competitive antagonism of binding to H1 receptors. In this issue, Weller and Maurer report that the H1 antagonist desloratadine possesses mast cell-stabilizing properties when challenged in an IgE-dependent or -independent fashion. Thus, desloratadine provides benefits that are independent of H1 receptor binding and based on mast cell stabilization.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19826448     DOI： 10.1038/jid.2009.256

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


  6 in total

1.  Unique immunomodulatory effects of azelastine on dendritic cells in vitro.

Authors:  S Schumacher; M Kietzmann; H Stark; W Bäumer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-08-15       Impact factor: 3.000

Review 2.  Histamine pharmacology: from Sir Henry Dale to the 21st century.

Authors:  Ekaterini Tiligada; Madeleine Ennis
Journal:  Br J Pharmacol       Date:  2018-12-02       Impact factor: 8.739

3.  Novel identified receptors on mast cells.

Authors:  Helena Migalovich-Sheikhet; Sheli Friedman; David Mankuta; Francesca Levi-Schaffer
Journal:  Front Immunol       Date:  2012-08-02       Impact factor: 7.561

4.  Topical antihistamines display potent anti-inflammatory activity linked in part to enhanced permeability barrier function.

Authors:  Tzu-Kai Lin; Mao-Qiang Man; Juan-Luis Santiago; Kyungho Park; Truus Roelandt; Yuko Oda; Melanie Hupe; Debra Crumrine; Hae-Jin Lee; Maria Gschwandtner; Jacob P Thyssen; Carles Trullas; Erwin Tschachler; Kenneth R Feingold; Peter M Elias
Journal:  J Invest Dermatol       Date:  2012-09-27       Impact factor: 8.551

5.  H1-antihistamines are associated with lower prevalence of radiographic knee osteoarthritis: a cross-sectional analysis of the Osteoarthritis Initiative data.

Authors:  Ivan Shirinsky; Valery Shirinsky
Journal:  Arthritis Res Ther       Date:  2018-06-07       Impact factor: 5.606

6.  Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects.

Authors:  Ranjan P Malhotra; Edward Meier; Gail Torkildsen; Paul J Gomes; Mark C Jasek
Journal:  Clin Ophthalmol       Date:  2019-02-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.